BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enlonstobart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enlonstobart\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07288814-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT07288814)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: Mitoxantrone Hydrochloride Li
 posome and Enlonstobart Combination Treatment in Patients With Relapsed or
  Refractory Peripheral T Cell Lymphoma (PTCL)\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 enlonstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07288814
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132217-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT06132217)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: A Study of Simmitinib Plus SG
 001 in Advanced Solid Tumors\nEstimated primary completion: 30 January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06132217
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136988-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT06136988)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: A Study of Docetaxel for Inje
 ction (Albumin-bound) and SG001 in Combination With Cisplatin and Simultan
 eous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Ca
 rcinoma.\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06136988
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07633873)
DESCRIPTION:Enlonstobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SY
 S6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chem
 otherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic N
 SCLC（SYNSTAR 04）\nEstimated primary completion: 30 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810114-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT07810114)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: Total Neoadjuvant mFOLFOX6 Plus
  Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherap
 y for High-Risk Mid-Rectal Locally Advanced Rectal Cancer\nEstimated prima
 ry completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enlonstobart#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07810114
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989671-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT06989671)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: SYS6002 Plus JMT101 and Enlonst
 obart Injection in Participants With HNSCC\nEstimated primary completion: 
 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enl
 onstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06989671
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662811-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07662811)
DESCRIPTION:Enlonstobart\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Th
 erapy for Squamous Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 enlonstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07662811
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714668-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT07714668)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: A Clinical Study of SYS6041 Com
 bination Therapy for Recurrent Ovarian Cancer\nEstimated primary completio
 n: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enl
 onstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07714668
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282509-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT07282509)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: Safety and Efficacy of Paclit
 axel Liposome Arterial Infusion Combined With Systemic Therapy for Second-
 Line Treatment of Advanced Liver Cancer\nEstimated primary completion: 26 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlonstoba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7282509
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998771-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT06998771)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: JSKN003 Combined Treatment of H
 ER2-positive Gastric Cancer\nEstimated primary completion: 30 June 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06998771
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254585-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT07254585)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: SYS6010 Combined With Enlonstob
 art In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma\nEsti
 mated primary completion: 30 June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07254585
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981858-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT06981858)
DESCRIPTION:Enlonstobart\, phase 2\, Cervical Cancer.\nStudy: A Single-Arm 
 Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Ch
 emoradiotherapy for Locally Advanced Cervical Cancer\nEstimated primary co
 mpletion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/enlonstobart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06981858
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672223-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07672223)
DESCRIPTION:Enlonstobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therap
 y in Non-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 
 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlon
 stobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07672223
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925021-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07925021)
DESCRIPTION:Enlonstobart\, phase 3.\nStudy: A Study of SYS6010 Combined Wit
 h Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Na
 sopharyngeal Carcinoma\nEstimated primary completion: 1 October 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07925021
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251062-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07251062)
DESCRIPTION:Enlonstobart\, phase 2/3.\nStudy: A Study of SYS6010\, Enlonsto
 bart\, and Chemotherapy for First-Line Treatment of Esophageal Squamous Ce
 ll Carcinoma.\nEstimated primary completion: 30 December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07251062
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924111-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07924111)
DESCRIPTION:Enlonstobart\, phase 3.\nStudy: A Randomized\, Controlled\, Dou
 ble-Blind\, Multicenter Phase III Clinical Trial to Evaluate the Efficacy 
 and Safety of Enlonstobart\, With or Without SYS6010 as Adjuvant Therapy\,
  in Participants With Pathologically Residual Esophageal Squamous Cell Car
 cinoma Following Complete Surgical Resection\nEstimated primary completion
 : 30 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nlonstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07924111
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183865-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20300309
DTEND;VALUE=DATE:20300310
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT07183865)
DESCRIPTION:Enlonstobart\, phase 2.\nStudy: Hypofractionated Radiotherapy C
 ombined With NALIRIF\, PD-1 Antibody in Locally Recurrent Rectal Cancer(NO
 VELTY-R)\nEstimated primary completion: 9 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07183865
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585279-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07585279)
DESCRIPTION:Enlonstobart\, phase 2/3.\nStudy: A Clinical Study of Liposomal
  Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer\nEstim
 ated primary completion: 28 February 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07585279
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332533-2291@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07332533)
DESCRIPTION:Enlonstobart\, phase 2/3.\nStudy: A Study of KN026-based Combin
 ation Therapy in HER2-positive Gastric Cancer\nEstimated primary completio
 n: 30 June 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlo
 nstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07332533
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
